Comments
Glenmark Pharmaceuticals has reported a consolidated net profit of Rs 55.85 crore for the second quarter ended September 30, 2011.
The company had posted a net profit of Rs 86.17 crore for the quarter ended September 30, 2010 Glenmark Pharmaceuticals said in a filing to the BSE.
“The net profit number is not comparable as there was a one-time exceptional expense amounting to Rs 131.68 crore and also due to (mark to market) MTM losses on account of foreign currency loans,” Glenmark said.
The one-time expense was for the purchase option election with respect to its royalty agreement with Paul Capital for its dermatology portfolio in the US, it added.
Consolidated net sales of the company stood at Rs 1,055.44 crore during the quarter under review compared with Rs 723.57 crore in the corresponding quarter a year ago.
Meanwhile, the shares of Glenmark Pharmaceuticals were trading at Rs 318.05 in the afternoon trade on BSE today, down 0.97 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.